MWI strikes alliance with Trupanion; Assisi gets go-ahead from FDA for canine lymphoma drug;

> MWI Veterinary Supply ($MWIV) has selected Trupanion ($TRUP) as its preferred provider of pet insurance for members of its Distinct Advantage Program. Release

> The FDA has awarded Assisi Research Laboratories Minor Use Minor Species designation for asparaginase, a drug it is developing to treat multicentric lymphoma in dogs. Release

> Canada's food safety agency announced the mad cow discovered recently was born in 2009, two years after Ottawa implemented a feed ban meant to guard against the disease. Article

> The FDA announced that as of September 2014 it has received 5,000 complaints of illnesses associated with pet treats made in China, including 1,000 deaths of dogs, but that the volume of complaints has recently declined. Release

> U.S. senators Mike Crapo of Idaho and Debbie Stabenow of Michigan introduced the Veterinary Medicine Loan Repayment Program Enhancement Act (S. 440), which will exempt awards made under the program from federal income withholding tax. Article

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…